radiopharmaceuticals

Market Access

JP Morgan Week may not have produced megadeals this year, but it still yielded plenty of food for thought. Here's five quick insights from San Fran.

Oncology

Molecular recycling could transform the economics and innovation of oncology drug discovery.

Oncology

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.

Oncology

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

News

Clinical results with GEP-NET radioligand therapy AlphaMedix, a possible rival to Novartis' Lutathera, could lead to regulatory filings.

Oncology

Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.